Filter
719
Text search:
drug
formulations
Featured
Recommendations
91
New Publications
210
Language
Document type
No document type
399
Guidelines
150
Studies & Reports
94
Manuals
37
Training Material
13
Strategic & Response Plan
10
Fact sheets
9
Situation Updates
2
Resource Platforms
2
Brochures
1
App
1
Infographics
1
Countries / Regions
India
51
Kenya
28
Global
23
Ethiopia
15
South Africa
15
Malawi
15
Western and Central Europe
12
Africa
12
Tanzania
11
Uganda
10
Nepal
10
Bangladesh
10
Sierra Leone
9
Nigeria
8
Zimbabwe
8
Zambia
8
Namibia
8
Liberia
7
Ghana
7
Philippines
7
Rwanda
7
Myanmar / Burma
7
South–East Asia Region
6
Latin America and the Carribbean
6
Eastern Europe
6
Cameroon
4
Cambodia
4
Eswatini/ Swaziland
4
Senegal
3
Haiti
3
Syria
3
Benin
3
Botswana
3
Burkina Faso
2
Indonesia
2
East and Southern Africa
2
Middle East and North Africa
2
Russia
2
Congo, Democratic Republic of
1
Mali
1
Côte d’Ivoire / Ivory Coast
1
Niger
1
Pakistan
1
South Sudan
1
Afghanistan
1
Thailand
1
Malaysia
1
Mozambique
1
Argentina
1
Peru
1
Brazil
1
Ukraine
1
Colombia
1
Bolivia
1
Madagascar
1
Lesotho
1
Sri Lanka
1
Chile
1
Yemen
1
Western Pacific Region
1
Eastern Europe and Central Asia
1
Paraguay
1
Bhutan
1
Venezuela
1
Congo-Brazzaville
1
Tajikistan
1
Australia
1
Georgia
1
North America
1
France
1
Authors & Publishers
Publication Years
Category
Countries
258
Clinical Guidelines
129
Women & Child Health
33
Public Health
32
Key Resources
19
Pharmacy & Technologies
15
Capacity Building
9
Toolboxes
HIV
105
TB
92
Pharmacy
63
AMR
40
Mental Health
32
NTDs
32
COVID-19
15
NCDs
15
Malaria
13
Rapid Response
9
Caregiver
9
Ebola & Marburg
8
Refugee
5
Planetary Health
5
Disability
4
Conflict
4
2.0 Rapid Response
4
Cholera
3
Polio
3
Health Financing Toolbox
3
Zika
2
Specific Hazards
2
Global Health Education
2
Technical information note. Ensuring an uninterrupted supply of quality-assured, affordable anti-TB
drugs and diagnostics to the world
Policy brief. July 2020
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB,
...
Accessed: 07.11.2019
A survival guide for clinicans.
3rd edition.
First Revised Edition
March 2000
ATIC Newsletter, Vol 15, Issue 1,
February 2022.
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination
Accessed: 08.10.2019
The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as
...
Table of contents:
- Preface
- Introductory note and acknowledgements
- Commentary
- Chapter 1: Drug supply and the market
- Chapter 2: Drug use prevalence and trends
- Chapter 3:
...
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.
Division of Tuberculosis Elimination.
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely
...